JP2016513703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513703A5 JP2016513703A5 JP2016502479A JP2016502479A JP2016513703A5 JP 2016513703 A5 JP2016513703 A5 JP 2016513703A5 JP 2016502479 A JP2016502479 A JP 2016502479A JP 2016502479 A JP2016502479 A JP 2016502479A JP 2016513703 A5 JP2016513703 A5 JP 2016513703A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition
- infected
- hcv genotype
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 23
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000001447 compensatory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| US61/783,437 | 2013-03-14 | ||
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087535A Division JP2019167347A (ja) | 2013-03-14 | 2019-05-07 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
| JP2019135865A Division JP2019214585A (ja) | 2013-03-14 | 2019-07-24 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513703A JP2016513703A (ja) | 2016-05-16 |
| JP2016513703A5 true JP2016513703A5 (enExample) | 2017-04-13 |
| JP6563894B2 JP6563894B2 (ja) | 2019-08-21 |
Family
ID=50771575
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502479A Expired - Fee Related JP6563894B2 (ja) | 2013-03-14 | 2014-03-14 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
| JP2019087535A Pending JP2019167347A (ja) | 2013-03-14 | 2019-05-07 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
| JP2019135865A Pending JP2019214585A (ja) | 2013-03-14 | 2019-07-24 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087535A Pending JP2019167347A (ja) | 2013-03-14 | 2019-05-07 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
| JP2019135865A Pending JP2019214585A (ja) | 2013-03-14 | 2019-07-24 | Ｈｃｖ患者を治療するための直接的に作用する抗ウイルス剤とリバビリンとの併用 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (enExample) |
| EP (4) | EP2968302B9 (enExample) |
| JP (3) | JP6563894B2 (enExample) |
| KR (2) | KR20180045055A (enExample) |
| CN (3) | CN108187056A (enExample) |
| AU (3) | AU2014239322B2 (enExample) |
| BR (1) | BR112015020918A2 (enExample) |
| CA (1) | CA2901818C (enExample) |
| CY (1) | CY1121474T1 (enExample) |
| DK (1) | DK2968302T3 (enExample) |
| EA (2) | EA030482B1 (enExample) |
| ES (1) | ES2654109T3 (enExample) |
| HK (1) | HK1255257A1 (enExample) |
| HR (1) | HRP20171898T1 (enExample) |
| HU (1) | HUE036069T2 (enExample) |
| IL (2) | IL240445B (enExample) |
| LT (1) | LT2968302T (enExample) |
| MX (1) | MX2015012536A (enExample) |
| NO (1) | NO3090119T3 (enExample) |
| PL (1) | PL2968302T3 (enExample) |
| PT (1) | PT2968302T (enExample) |
| RS (1) | RS56735B1 (enExample) |
| SG (2) | SG11201507361YA (enExample) |
| SI (1) | SI2968302T1 (enExample) |
| SM (1) | SMT201800017T1 (enExample) |
| TW (2) | TWI678205B (enExample) |
| WO (1) | WO2014152635A1 (enExample) |
| ZA (1) | ZA201705080B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| HUE036069T2 (hu) | 2013-03-14 | 2018-06-28 | Abbvie Inc | Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére |
| WO2015061742A2 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| CA2943054A1 (en) * | 2014-04-02 | 2015-10-08 | Abbvie Inc. | Methods for treating hcv |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| DK3383662T3 (da) | 2016-01-08 | 2020-10-26 | Entrust Datacard Corp | Kortudskrivningsmekanisme med kortreturneringsvej |
| CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| BR112019005725A2 (pt) * | 2016-09-23 | 2019-07-09 | Abbvie Inc | ajuste de dose |
| JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置する方法 |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| EP3773753A4 (en) * | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010013522A (es) * | 2008-06-10 | 2011-05-03 | Janssen Pharmaceutica Nv | Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c. |
| RS52854B (sr) * | 2009-06-11 | 2013-12-31 | Abbvie Bahamas Limited | Inhibitori hepatitis c virusa |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| UY38339A (es) | 2010-09-21 | 2020-12-31 | Enanta Pharm Inc | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| CH707030B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV |
| HUE036069T2 (hu) | 2013-03-14 | 2018-06-28 | Abbvie Inc | Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére |
-
2014
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 PL PL14725812T patent/PL2968302T3/pl unknown
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 SM SM20180017T patent/SMT201800017T1/it unknown
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko not_active Abandoned
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko not_active Expired - Fee Related
- 2014-03-14 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en not_active Ceased
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513703A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| JP2015024998A5 (enExample) | ||
| JP2017057230A5 (enExample) | ||
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| DK2583677T1 (da) | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon | |
| DK2583680T1 (da) | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV | |
| JP2016508134A5 (enExample) | ||
| RU2015114543A (ru) | Способы лечения гепатита с | |
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| JP2013529627A5 (enExample) | ||
| RU2015114566A (ru) | Способы лечения гепатита с | |
| JP2015516419A5 (enExample) | ||
| Puri et al. | Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: update 2016 | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| EA201692507A1 (ru) | Фармацевтические комбинации софосбувира и рибавирина | |
| JP2018513175A5 (enExample) | ||
| WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| MX2018000213A (es) | Metodos para tratar el vhc. |